CCRP Clinical Trials

Search for keyword:      



Basket TrialsBiomarker AnalysisEAY131FOPENMATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations
Basket TrialsBiomarker AnalysisEAY131GOPENMATCH Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer)
Basket TrialsBiomarker AnalysisEAY131VOPENMATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
Basket TrialsBiomarker AnalysisEAQ152OPENCOMET - COMMUNICATION AND EDUCATION IN TUMOR PROFILING: A RANDOMIZED STUDY OF PRE-TEST GENETIC EDUCATION V. USUAL CARE IN TUMOR PROFILING FOR ADVANCED CANCER AND A PILOT STUDY OF REMOTE GENETIC COUNSELING FOR PARTICIPANTS WITH POTENTIAL GERMLINE MUTATIONS
Basket TrialsBiomarker AnalysisEAY131OPENMolecular Analysis for Therapy Choice (MATCH)
Basket TrialsBiomarker AnalysisEAY131AOPENMATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
Basket TrialsBiomarker AnalysisEAY131-K1OPENMATCH Treatment Subprotocol K1: Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Amplifications
Basket TrialsBiomarker AnalysisEAY131EOPENMATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
Basket TrialsBiomarker AnalysisEAY131HSUSPENDEDMATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with tumors with BRAF V600E or V600K mutations (excluding melanoma and thyroid cancer)
Basket TrialsBiomarker AnalysisEAY131C1SUSPENDEDEAY131-C1, Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification.
BreastBreastA011202(CTSU/Alliance)OPENA Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
BreastBreastA221405OPENA Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy (POSITIVE)
BreastBreastAFT-25OPENComparison of operative to monitoring and endocrine therapy (COMET) trial for low risk DCIS: a phase III prospective randomized trial
BreastBreastNRG- BR002OPENA Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
BreastBreastS1418OPENA RANDOMIZED, PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MK-3475 (PEMBROLIZUMAB) AS ADJUVANT THERAPY FOR TRIPLE RECEPTOR-NEGATIVE BREAST CANCER WITH ? 1 CM RESIDUAL INVASIVE CANCER OR POSITIVE LYMPH NODES (YPN+) AFTER NEOADJUVANT CHEMOTHERAPY
BreastBreastA221505OPENPHASE III RANDOMIZED TRIAL OF HYPOFRACTIONATED POST MASTECTOMY RADIATION WITH BREAST RECONSTRUCTION
BreastBreastNRG-BR005OPENA PHASE II TRIAL ASSESSING THE ACCURACY OF TUMOR BED BIOPSIES IN PREDICTING PATHOLOGIC RESPONSE IN PATIENTS WITH CLINICAL/RADIOLOGIC COMPLETE RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY IN ORDER TO EXPLORE THE FEASIBILITY OF BREAST CONSERVING TREATMENT WITHOU
BreastBreastA011502OPENA randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for node-positive HER2 negative breast cancer: The ABC trial
BreastBreastEA1131OPENA Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
BreastBreastS1416OPENPHASE II RANDOMIZED PLACEBO-CONTROLLED TRIAL OF CISPLATIN WITH OR WITHOUT ABT-888 (VELIPARIB) IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER AND/OR BRCA MUTATION-ASSOCIATED BREAST CANCER
BreastBreastMA.39OPENTAILOR RT: A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK NODE POSITIVE BREAST CANCER
BreastBreastA011401OPENRANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF WEIGHT LOSS IN ADJUVANT TREATMENT OF OVERWEIGHT AND OBESE WOMEN WITH EARLY BREAST CANCER
BreastBreastA171601OPENA PHASE II TRIAL ASSESSING THE TOLERABILITY OF PALBOCICLIB IN COMBINATION WITH LETROZOLE OR FULVESTRANT IN PATIENTS AGED 70 AND OLDER WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER
BreastBreastA211601OPENEVALUATION OF MAMMOGRAPHIC BREAST DENSITY EFFECT OF ASPIRIN: A COMPANION STUDY TO ALLIANCE STUDY A011502
BreastBreastS1706OPENA PHASE II RANDOMIZED TRIAL OF OLAPARIB (NSC-747856) ADMINISTERED CONCURRENTLY WITH RADIOTHERAPY VERSUS RADIOTHERAPY ALONE FOR INFLAMMATORY BREAST CANCER
BreastBreastS1703OPENRANDOMIZED NON-INFERIORITY TRIAL COMPARING OVERALL SURVIVAL OF PATIENTS MONITORED WITH SERUM TUMOR MARKER DIRECTED DISEASE MONITORING (STMDDM) VERSUS USUAL CARE IN PATIENTS WITH METASTATIC HORMONE RECEPTOR POSITIVE BREAST CANCER
BreastBreast - AdjuvantS1207 (CTSU/SWOG)OPENPhase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of EVEROLIMUS in Patients with High-Risk Hormone Receptor-Positive AND HER2/neu Negative Breast Cancer.
BreastBreast - AdjuvantNRG-BR003OPENA Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
BreastBreast - NeoadjuvantB-51OPENA Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axill
BreastBreast - NeoadjuvantA011106 (CTSU/Alliance)OPENALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study.
BreastCANCER CONTROL/PREVENTIONEA1151 (TMIST)OPENTomosynthesis Mammographic Imaging Screening Trial (TMIST)
GIColonA021502OPENRANDOMIZED TRIAL OF STANDARD CHEMOTHERAPY ALONE OR COMBINED WITH ATEZOLIZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE III COLON CANCER AND DEFICIENT DNA MISMATCH REPAIR (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer)
GIColonS0820 (CTSU/SWOG)OPENA Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III-Preventing Adenomas of the Colon with Eflornithine
GICOLORECTALS1613OPENA RANDOMIZED PHASE II STUDY OF TRASTUZUMAB AND PERTUZUMAB (TP) COMPARED TO CETUXIMAB AND IRINOTECAN (CETIRI) IN ADVANCED/METASTATIC COLORECTAL CANCER (MCRC) WITH HER-2 AMPLIFICATION
GICOLORECTALGI004OPENCOLORECTAL CANCER METASTATIC dMMR IMMUNO-THERAPY (COMMIT) STUDY: A RANDOMIZED PHASE III STUDY OF mFOLFOX6/BEVACIZUMAB COMBINATION CHEMOTHERAPY WITH OR WITHOUT ATEZOLIZUMAB OR ATEZOLIZUMAB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH DEFICIENT
GICOLORECTALEAQ162CDOPENLongitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent
GIRectalNRG-GI002OPENA PHASE II CLINICAL TRIAL PLATFORM OF SENSITIZATION UTILIZING TOTAL NEOADJUVANT THERAPY (TNT) IN RECTAL CANCER
GIRectalEA2165OPENA RANDOMIZED PHASE II STUDY OF NIVOLUMAB AFTER COMBINED MODALITY THERAPY (CMT) IN HIGH RISK ANAL CANCER
GUPROSTATEEA8153OPENCabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
Gynecological OncologyGynecology - EndometrialGY012SUSPENDEDA Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
Gynecological OncologyGynecology - OvarianGY009OPENRANDOMIZED, PHASE II/III STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN AND CTEP-SUPPLIED ATEZOLIZUMAB (IND #134427) VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN/BEVACIZUMAB AND CTEP-SUPPLIED ATEZOLIZUMAB VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN/BEVACIZUMAB IN PLATINUM
Head and NeckHead and NeckNRG HN001OPENRandomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Heme MalignancyAL AmyloidosisS1702OPENA PHASE II STUDY OF ISATUXIMAB (SAR650984) (NSC-795145) FOR PATIENTS WITH PREVIOUSLY TREATED AL AMYLOIDOSIS
Heme MalignancyLeukemia - Acute Lymphocytic Leukemia (ALL)ACCL16N1CDOPENDocumentation and Delivery of Guideline-Consistent Treatment in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia (ALL)
Heme MalignancyLeukemia - Acute Promyelocytic Leukemia (APL)EA9131OPENA Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)
Heme MalignancyLeukemia - Chronic Myelogenic Leukemia (CML)S1712OPENA RANDOMIZED PHASE II STUDY OF RUXOLITINIB (NSC-752295) IN COMBINATION WITH BCR-ABL TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH MOLECULAR EVIDENCE OF DISEASE
Heme MalignancyLEUKEMIA/MDSNHLBI-MDSOPENTHE NATIONAL MYELODYSPLASTIC SYNDROMES (MDS) STUDY
Heme MalignancyLEUKEMIA/MDSEA9161OPENA RANDOMIZED PHASE III STUDY OF THE ADDITION OF VENETOCLAX TO IBRUTINIB AND OBINUTUZUMAB VERSUS IBRUTINIB AND OBINUTUZUMAB IN UNTREATED YOUNGER PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Heme MalignancyLymphomaEA4151OPENA Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete R
Heme MalignancyLymphomaS1608OPENRANDOMIZED PHASE II TRIAL IN EARLY RELAPSING OR REFRACTORY FOLLICULAR LYMPHOMA
Heme MalignancyLymphomaE4412OPENA PHASE I STUDY WITH AN EXPANSION COHORT/RANDOMIZED PHASE II STUDY OF THE COMBINATIONS OF IPILIMUMAB, NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA
Heme MalignancyLymphoma - B-cell LymphomaA051301SUSPENDEDA randomized double-blind phase III study of ibrutinib during and following autologous stem cell transplantation versus placebo in patients with relapsed or refractory diffuse large B-cell lymphoma of the activated B-cell subtype
Multiple Disease SitesMultiple Disease SitesNRG-CC004OPENPHASE II DOUBLE BLIND DOSE FINDING TRIAL OF BUPROPION VERSUS PLACEBO FOR SEXUAL DESIRE IN WOMEN WITH BREAST OR GYNECOLOGIC CANCER
Multiple Disease SitesMultiple Disease SitesS1609OPENDART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS
NeuroendocrineNeuroendocrineA021602OPENRANDOMIZED, DOUBLE-BLINDED PHASE III STUDY OF CABOZANTINIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS AFTER PROGRESSION ON EVEROLIMUS (CABINET)
SkinMelanomaS1616OPENA PHASE II RANDOMIZED STUDY OF NIVOLUMAB (NSC-748726) WITH IPILIMUMAB (NSC-732442) OR IPILIMUMAB ALONE IN ADVANCED MELANOMA PATIENTS REFRACTORY TO AN ANTI-PD1 OR ANTI-PD-L1 AGENT
SkinMelanomaEA6134OPENA Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
SkinMelanomaS1320OPENA Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
SkinMelanomaEA6141SUSPENDEDRandomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Symptom Mgmt/ Prevention/ScreenCancer Control E1Q11OPENEROS: Engendering Reproductive Health within Oncologic Survivorship
Symptom Mgmt/ Prevention/ScreenCancer Control DCP-001OPENUse of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Symptom Mgmt/ Prevention/ScreenSymptom Mgmt/ Prevention/ScreeningA221602OPENOLANZAPINEWITH ORWITHOUT FOSAPREPITANT FOR THE PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY (HEC): A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
ThoracicLUNGA151216OPENAdjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) SCREENING ARM
ThoracicLUNGNRG-LU002OPENMAINTENANCE SYSTEMIC THERAPY VERSUS CONSOLIDATIVE STEREOTACTIC BODY RADIATION THERAPY (SBRT) PLUS MAINTENANCE SYSTEMIC THERAPY FOR LIMITED METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE II/III TRIAL
ThoracicLung - Non-Small Cell Lung CancerEA5142OPENAdjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers (ALCHEMIST EGFR AND ALK NEG)
ThoracicLung - Non-Small Cell Lung CancerA081105 (CTSU/Alliance)OPENRandomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) (ALCHEMIST EGFR +)
ThoracicLung - Non-Small Cell Lung CancerE4512OPENA Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (ALCHEMIST)
ThoracicLung - Non-Small Cell Lung CancerA221504OPENA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY OF AN ORAL, SELECTIVE PERIPHERAL OPIOID RECEPTOR ANTAGONIST IN ADVANCED NON-SMALL CELL LUNG CANCER (ADENOCARCINOMA)
ThoracicLung - Small Cell Lung CancerNRG-CC003OPENRANDOMIZED PHASE II/III TRIAL OF PROPHYLACTIC CRANIAL IRRADIATION WITH OR WITHOUT HIPPOCAMPAL AVOIDANCE FOR SMALL CELL LUNG CANCER
ThoracicLung - Small Cell Lung Cancer30610 (CTSU/CALGB)OPENPhase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide.